Metachromatic leukodystrophy
Metachromatic leukodystrophy
Also known as:MLD; arylsulfatase A deficiency; China Second Rare Disease Catalog item 49
Metachromatic leukodystrophy is usually an ARSA-related lysosomal storage disease in which sulfatides build up and progressively damage central and peripheral nerve myelin.
Start Here
A quick guide to the next step: which department to start with, what to prepare, and what to ask.
Children with regression, gait change, repeated falls, or learning and behavior changes should see pediatric neurology. Adults with psychiatric or cognitive onset need neurology and psychiatry coordination.
MLD is caused by deficient arylsulfatase A function, leading to sulfatide buildup that affects walking, language, learning, behavior, swallowing, vision, hearing, and peripheral nerves.
The treatment window matters. Presymptomatic or very early children may be assessed for stem cell transplant or gene therapy, while advanced disease relies more on symptom, rehabilitation, nutrition, and comfort care.
It is usually autosomal recessive, most often involving ARSA and rarely PSAP. Parents are typically carriers, so recurrence risk needs genetic counseling.
Early disease can look like cerebral palsy, developmental delay, peripheral neuropathy, school problems, behavior disorders, or psychiatric illness. Low ARSA activity also needs confirmation to avoid pseudo-deficiency misdiagnosis.
This page helps patients and families organize care leads. It does not replace a clinician’s diagnosis or treatment plan. For testing, medication, referrals, emergency care, and support applications, follow qualified clinicians, medical institutions, support organizations, and official sources.
Diagnosis Path
Organized around the practical patient journey: identify clues, avoid common delays, then prepare for care.
When to Suspect It
- A child who had learned to walk begins falling, develops gait problems, tone changes, or loses language or motor skills.
- A school-age child develops falling grades, attention or behavior change, plus movement or peripheral nerve problems.
- A teenager or adult has unexplained psychiatric symptoms, cognitive decline, or work or school decline with white-matter MRI changes.
- Family history of MLD, leukodystrophy, early neurodegeneration, or unexplained childhood death.
Common Wrong Turns
- Treating only as cerebral palsy, autism, psychological illness, or ordinary neuropathy without repeat brain MRI and metabolic or genetic testing.
- Diagnosing MLD from low ARSA activity alone without urine sulfatides and genetic confirmation.
- Referral after major functional loss, when transplant or gene therapy windows may have closed.
Departments to Start With
- Pediatric neurology
- Neurology
- Medical genetics
- Rehabilitation medicine
Before the Visit
- Prepare a developmental and regression timeline, walking and language changes, school or behavior changes, seizures, and swallowing problems.
- Bring brain MRI images, nerve conduction or EMG studies, eye and hearing evaluations, and metabolic screening results.
- Record family history, consanguinity, sibling symptoms, miscarriages, or childhood deaths.
- If treatment windows are being discussed, bring recent functional assessments and the pace of decline.
Tests to Ask About
- Brain MRI white-matter pattern and peripheral nerve conduction testing.
- Arylsulfatase A enzyme activity, urine sulfatides, and ARSA/PSAP gene testing.
- How pseudo-ARSA deficiency will be ruled out.
- Whether stem cell transplant or gene therapy evaluation is still appropriate and what baseline tests are required.
Questions for the Doctor
- Is this late-infantile, juvenile, or adult MLD, and what stage is it now?
- Is the diagnosis supported by enzyme, urine sulfatide, and genetic evidence, and has pseudo-deficiency been excluded?
- Is there still a transplant or gene therapy evaluation window? If not, what supportive care should start now?
- What carrier testing, prenatal diagnosis, or preimplantation counseling should relatives consider?
Basic Information
Medical Notes
More complete medical explanations are kept here for discussion with clinicians.
Symptoms
MLD is often grouped by age at onset: late-infantile, juvenile, and adult. Late-infantile disease commonly causes gait problems, repeated falls, language or motor regression, tone changes, and peripheral neuropathy. Juvenile disease may begin with school decline, behavior change, and worsening coordination.
Adult-onset disease can begin with psychiatric symptoms, personality change, cognitive decline, or reduced work or school function. Progression may bring seizures, swallowing difficulty, vision or hearing loss, spasticity, pain, nutrition problems, and severe disability.
Diagnosis
Diagnosis combines the regressive clinical course, brain MRI white-matter changes, peripheral nerve involvement, ARSA enzyme activity, urine sulfatides, and genetic testing. ARSA is the most common gene, while PSAP accounts for rare cases.
Low ARSA activity alone is not enough, because pseudoarylsulfatase deficiency can lower enzyme activity without causing classic MLD. Clinicians usually integrate enzyme, urine sulfatide, and pathogenic variant evidence, while excluding other leukodystrophies, mitochondrial disease, inflammatory demyelination, and psychiatric disorders.
Treatment
Treatment options depend strongly on disease stage. Some presymptomatic or very early, more slowly progressive patients may be evaluated for hematopoietic stem cell transplant at experienced centers. In some countries, autologous hematopoietic stem cell gene therapy is approved for eligible children, but access, criteria, and cost must be checked case by case.
For people with clear neurologic progression, care focuses on seizure control, tone and pain management, swallowing and nutrition support, respiratory care, physical, occupational, and speech therapy, assistive devices, psychological support, and comfort-focused care. Early goals-of-care planning can reduce repeated crises.
Long-term Care
Long-term follow-up often involves neurology, genetics, rehabilitation, nutrition, pulmonology, gastroenterology, orthopedics, and palliative support. Caregivers can track swallowing, weight, sleep, pain, spasticity, seizures, and infections to guide adjustments.
Families may need school or workplace support, rehabilitation resources, nursing training, and advance care planning. Preventing aspiration, pressure injury, malnutrition, and uncontrolled pain becomes increasingly important as disease progresses.
Fertility and Family
MLD is usually autosomal recessive. When both parents are carriers, each pregnancy has a 25% chance of being affected. After diagnosis, parents, siblings, and reproductive-age relatives should be offered genetic counseling about carrier testing, prenatal diagnosis, and preimplantation genetic testing.
When to Seek Urgent Care
Urgent care is needed for repeated choking, aspiration pneumonia, breathing difficulty, persistent fever, status epilepticus, severe dehydration, inability to feed, uncontrolled pain, or major change in consciousness. People after transplant or gene therapy should also follow center-specific instructions for infection, blood count, and treatment-related risks.
Prognosis
MLD is usually progressive, and earlier-onset forms often decline faster. Early recognition of treatment windows and ongoing supportive care strongly affect function and quality of life.